While Jubilant Generics had already been shortlisted by Gilead to manufacture a generic version of Remdesivir, it has just received approval from India’s domestic regulator, DCGI, for the generic version of Remdesivir 100 mg/vial for restricted emergency use in India. This is intended to treat severe COVID-19. Jubilant Generics is a subsidiary of Jubilant Life.

Remdesivir will be marketed by Jubilant Generics under the brand name “JUBI-R” in India. It will distribute JUBI-R in Indian through its network and it is expected to be available by first week of August. The idea will be to manufacture on scale at affordable price. Under the deal with Gilead, Jubilant can sell Remdesivir in 127 countries including India.